Business
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A
Bioasis Announces Filing of Its First Quarter Financial Statements and MD&A.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n NEW HAVEN, Conn., July 29, 2022 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC. (TSX.V:BTI; OTCQB:BIOAF) (the “Company” or “Bioasis”), a biopharmaceutical company developing its proprietary xB3™ platform technology for the delivery of therapeutics across the blood-brain barrier (the “BBB”) announced today that it has filed its unaudited quarterly financial statements and management’s discussion and analysis for the period ended May 31, 2022. All are available under the Company’s profile on SEDAR and on the Company’s website at www.bioasis.us/investors/. On behalf of the Board of Directors of Bioasis Technologies Inc.Deborah Rathjen, Ph.D., Executive Chair of the Board Follow on:FacebookInstagramLinkedInTwitter BTI-FIN About BioasisBioasis Technologies Inc. is a biopharmaceutical company developing the xB3™ platform, a proprietary technology for the delivery of therapeutics across the blood brain barrier and the treatment of CNS disorders in areas of high unmet medical need, including brain cancers and neurodegenerative diseases. The delivery of therapeutics across the blood brain barrier represents the final frontier in treating neurological disorders. The in-house development programs at Bioasis are designed to develop symptomatic and disease-modifying treatments for brain-related diseases and disorders. For more information about the Company, please visit www.bioasis.us. Forward Looking Statements Certain statements in this press release contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 or forward-looking information under applicable Canadian securities legislation that may not be based on historical fact along with other statements containing the words “believe,” “may,” “plan,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect” and similar expressions. Such forward-looking statements or information involve known and unknown risks, uncertainties and other factors that may cause our actual results, events or developments, or industry results, to be materially different from any future results, events or developments express or implied by such forward-looking statements or ...